Thymosin α1 vs thymosin β4
Thymosin α1 and thymosin β4 share a name because both were first isolated from the same thymus extract, but they are unrelated in sequence, origin and function. This page compares their structures, biology, evidence base, regulatory status and analytical concerns.
The thymosins were named in the 1960s and 1970s after a series of peptides was purified from calf thymus extracts, particularly a preparation called thymosin fraction 5. The Greek letters reflect how the peptides separated during isoelectric focusing of that extract, not a shared structural family. Thymosin α1 and thymosin β4 both came out of this work, which is the only real connection between them.
Thymosin α1 is a 28-residue fragment of the larger protein prothymosin α and has been studied mainly as an immune modulator; as thymalfasin it is approved in several countries outside the US. Thymosin β4 is a 43-residue actin-binding peptide expressed in most cells and studied mainly in tissue-repair models. Treating them as interchangeable is a common naming error.
Side-by-side
| Attribute | Thymosin α1 | Thymosin β4 |
|---|---|---|
| Origin | Processed from prothymosin α; first isolated from thymus extract | Encoded by TMSB4X; first isolated from thymus extract, but expressed in most cells |
| Length | 28 residues | 43 residues |
| Structure | N-acetylated, highly acidic; no Cys, Met or Trp | N-acetylated (begins Ac-SDKP); one methionine; LKKTETQ actin-binding motif |
| Primary biology | Immune signaling; reported effects on T cells and dendritic cells, including Toll-like receptor pathways | Binds monomeric (G-) actin; cell migration and wound-repair pathways |
| Research areas | Immune response in infection, vaccine response and oncology settings | Corneal, skin and cardiac injury models; ophthalmic and topical trials |
| Evidence level | Approved outside the US; clinical data vary in quality by indication | Late-clinical trials of specific formulations; none approved |
| FDA / ex-US status | Not FDA-approved; approved in several countries as thymalfasin (Zadaxin) | Not FDA-approved; no approved product |
| WADA | Check the current WADA Prohibited List | Prohibited under S2 (thymosin β4 and its fragments) |
| Analytical pitfalls | Many acidic residues complicate ionization and charge-state assignment; salt form | Methionine oxidation; truncations; confusion with TB-500 fragment |
| Storage | Lyophilized at -20 °C, protected from moisture | Lyophilized at -20 °C, protected from light and moisture; avoid freeze-thaw |
A shared name, not a shared family
The thymosin nomenclature was applied to fractions of a crude thymus extract before the individual peptides were sequenced. Thymosin α1 later proved to be the N-terminal part of prothymosin α, a nuclear protein, while thymosin β4 belongs to a separate family of small actin-binding β-thymosins. Their sequences show no meaningful similarity, they are encoded by different genes and they are not processed from a common precursor. Thymosin β4 is also not specific to the thymus; it is among the most abundant peptides in many cell types.
Different biology and research directions
Thymosin α1 has been studied for effects on immune cell maturation and cytokine signaling, with proposed actions through Toll-like receptors on dendritic cells and other immune cells. Clinical research has focused on settings such as chronic viral hepatitis and vaccine response, and approved uses vary by country. Thymosin β4 is studied for its role in actin dynamics and cell migration, with animal work in wound, corneal and cardiac injury models and human trials of ophthalmic and topical formulations that produced mixed results.
Why the distinction matters in the lab
The two peptides have different lengths, compositions and expected masses, so a certificate of analysis for one cannot support the other. Thymosin α1 is strongly acidic and contains no oxidation-prone residues, while thymosin β4 has a methionine whose oxidation should be monitored. Each name also has its own confusions: thymosin α1 with its precursor prothymosin α, and thymosin β4 with the fragment sold as TB-500. See TB-500 vs thymosin β4 for that comparison.
Frequently asked questions
Are thymosin α1 and thymosin β4 related?
Only by name and history. Both were first identified in fractions of a calf thymus extract, and the Greek letters reflect how those fractions separated. Their sequences are unrelated, they come from different genes and precursors, and they have different biological roles: thymosin α1 in immune signaling and thymosin β4 in actin binding and cell migration.
Is thymosin α1 or thymosin β4 FDA approved?
Neither is approved by the FDA. Thymosin α1, as thymalfasin (Zadaxin), is approved in several countries outside the US, with indications that vary by country. Thymosin β4 has been tested in human trials of ophthalmic and topical formulations but has no approved product anywhere. US compounding status for both should be checked against current FDA lists.
Is TB-500 a form of thymosin α1?
No. TB-500 is derived from thymosin β4, most often the acetylated fragment Ac-LKKTETQ from its actin-binding region. It has no sequence relationship with thymosin α1. Confusing the names can lead to ordering or testing the wrong compound, so certificates of analysis should state the full sequence that was confirmed.
Full entries
- Thymosin α1
Thymosin α1 is a 28-amino-acid N-acetylated peptide derived from prothymosin α. Its synthetic form, thymalfasin (Zadaxin), is approved in several countries outside the US and has been studied as an immune modulator in clinical trials.
- Thymosin β4
Thymosin β4 is a naturally occurring 43-amino-acid peptide that binds monomeric actin and is abundant in many cell types. It has been studied in animal models of tissue repair and in human trials of ophthalmic and topical formulations, and is not approved.
Cite this page